Overview and Scope
Inhalable drugs refer to medications delivered directly into the respiratory system through inhalation to get high. These drugs are designed to be inhaled into the lungs, where they can be rapidly absorbed into the bloodstream and exert their therapeutic effects.
Sizing and Forecast
The inhalable drugs market size has grown strongly in recent years. It will grow from $33.29 billion in 2023 to $35.48 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to increased geriatric population, patient preference for non-invasive treatments, increased focus on respiratory health, emerging markets growth.
The inhalable drugs market size is expected to see strong growth in the next few years. It will grow to $46.19 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to growing healthcare spending, growing demand for biologics, increasing focus on personalized medicine, regulatory support for orphan drugs. Major trends in the forecast period include advanced respiratory drugs in veterinary medicine, technological innovation, improved reimbursement policies.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/inhalable-drugs-global-market-report
The inhalable drugs market covered in this report is segmented –
1) By Product: Aerosol, Dry Powder Formulation, Spray
2) By Distribution Channel: Hospital Pharmacy, Pharmacy Stores, Other Distribution Channels
3) By Application: Respiratory Diseases, Non-Respiratory Diseases
4) By End Users: Adults, Pediatric, Geriatric
North America was the largest region in the inhalable drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhalable drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=12490&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of respiratory diseases is expected to propel the growth of the inhalable drug market going forward. Respiratory diseases are medical conditions that affect the respiratory system, which includes the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. Inhalable drugs are a crucial and effective treatment option for several respiratory disorders as they deliver medication directly to the lungs. For instance, in June 2023, according to the Australian Institute of Health and Welfare, an Australia-based government agency, there were approximately 6,551 deaths or 135 deaths per 100,000 population caused by respiratory chronic conditions in Australia in 2021, representing 27.1% of all deaths. Furthermore, chronic obstructive pulmonary disease (COPD) accounted for 2.6% of underlying-cause respiratory deaths, respectively. Therefore, the increasing prevalence of respiratory diseases will drive the future inhalable drug market.
Key Industry Players
Major companies operating in the inhalable drugs market report are Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline Plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH,Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Mylan N.V., Catalent Inc., Sumitomo Pharma Co. Ltd., Intertek Group plc, AptarGroup Inc., Cipla Inc., Glenmark Pharmaceuticals Inc., Piramal Pharma Ltd., Zambon S.p.A., Sunovion Pharmaceuticals Inc., Nelson Laboratories LLC, Vectura Group Limited, Abiogen Pharma, Quotient Sciences, AeroGen Pharma, CareFusion Corporation, Alaxia S.A.S., Pharmaxis Ltd., Avalyn Pharma Inc., TFF Pharmaceuticals Inc.
The inhalable drugs market report table of contents includes:
1. Executive Summary
2. Inhalable Drugs Characteristics
3. Inhalable Drugs Trends And Strategies
4. Inhalable Drugs – Macro Economic Scenario
5. Global Inhalable Drugs Size and Growth
…..
32. Global Inhalable Drugs Competitive Benchmarking
33. Global Inhalable Drugs Competitive Dashboard
34. Key Mergers And Acquisitions In The Inhalable Drugs
35. Inhalable Drugs Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
